clinical trial – Page 201 – Communicable Diseases Research

Hydrogen: A Potential New Adjuvant Therapy for COVID-19 Patients

Pharmacology

Published on 2020-10-152022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

Impact of Chronic Use of Antimalarials on SARS-CoV-2 Infection in Patients With Immune-Mediated Rheumatic Diseases: Protocol for a Multicentric Observational Cohort Study

Protocol

Published on 2020-10-142022-10-29
Journal: JMIR Research Protocols [Category] COVID-19,

[키워드] Analysis Anosmia antimalarial arthropathy baseline benefit Brazil caused Chloroquine chronic clinical Clinical findings clinical trial collected Comorbidities Concomitant medication coronavirus cough COVID-19 COVID-19 outbreak COVID-19 patient database death demographic data diagnosed disease drug Dyspnea effective enrolled epidemiological Fever FIVE form Health Service Hospitalization Hydroxychloroquine Identifier immune system Immune-mediated immunology Impact include Inclusion individual information inhibiting intensive care knowledge lack large sample mechanisms Mortality objective Observational Observational cohort study Osteoarthritis outcome pathophysiology Patient patients treated pharmacological pharmacological management protective effect protocol recorded Region Registration registry report Research Result rheumatic disease Rheumatic diseases rheumatology SARS-CoV-2 SARS-COV-2 infection Scientific community shown the disease Treatment virus was done
[DOI] 10.2196/23532 PMC 바로가기 [Article Type] Protocol

A Review of the Progress and Challenges of Developing a Vaccine for COVID-19

COVID-19 백신 개발의 진행 상황 및 과제 검토

Review

Published on 2020-10-142022-09-11
Journal: Frontiers in Immunology [Category] MERS, SARS, 신약개발, 진단, 치료기술,

[키워드] acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition affecting anticipated ARDS AstraZeneca Asymptomatic AZD1222 cause challenge China claimed clinical trial clinical trials CoronaVac coronavirus Coverage COVID-19 COVID-19 pandemic death develop Developing DNA vaccine effective Efficacy effort eight focus global pandemic hygiene immunogenic immunological implication inactivated virus particle vaccine individual Infectious disease International life measure Moderna mRNA-1273 Neutralizing antibodies non-replication viral vector vaccine Novel coronavirus Phase 1 Pneumonia potential limitation potential limitations present Progress PROTECT referred to Repurposed drugs required respiratory respiratory distress Respiratory distress syndrome review RNA vaccine SARS-CoV-2 SARS-CoV-2 vaccine severe acute respiratory syndrome Coronavirus Sinovac social distancing Spread Stage Symptom syndrome Vaccine vaccine candidate vaccine candidates Vaccine development vaccine platform Vaccines vulnerable population Wuhan
[DOI] 10.3389/fimmu.2020.585354 PMC 바로가기 [Article Type] Review

Lack of tocilizumab effect on mortality in COVID19 patients

Article

Published on 2020-10-132022-10-04
Journal: Scientific Reports [Category] Coronavirus, MERS, SARS, 바이오마커,

[키워드] alterations clinical trial correlated COVID-19 patient COVID-19 pneumonia patient COVID19 patient Cytokine release syndrome Diseases elevated IL-6 IL-6 level lack Mortality Outcomes research reflect Tocilizumab tocilizumab administration
[DOI] 10.1038/s41598-020-74328-x PMC 바로가기 [Article Type] Article

The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial

입원한 COVID-19 환자의 결과 개선에 대한 파모티딘의 효능: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-10-132022-08-13
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] Alanine Alanine transaminase alcoholism All participant All participants allergies allergy allocation approved ARMS aspartate Aspartate transaminase assigned assumption Bandar Abba Bandar Abbas baseline Blinding block randomization blood count Care Chronic kidney disease clearance clinical clinical trial clinical trials code Committee company comparator Comparator group complete blood count concealed control group control groups COVID-19 COVID-19 patient COVID-19 patients creatinine creatinine clearance criteria Dasatinib dialysis discharge dissemination dosage drug therapy electrocardiogram element eligibility criteria End-stage renal disease ethics committee Evidence evidence of excluded expected Famotidine G6PD Glucose Glucose 6 phosphate grouping groups Hepatitis hepatitis C Hospitalized Immunocompromised Immunocompromised patients Infection Intervention Kidney disease Lactate lactate dehydrogenase lead limit Liver disease Local lung infiltration maximum Medical Science Medical Sciences moderate need for dialysis Neratinib normal limit number objective online tool oral contraceptives outcome outcome assessor outcome assessors oxygen oxygen saturation Ozanimod participant Patient patients patients with COVID-19 Pazopanib PCR test pharmaceutical Pharmaceutical Company phosphate Placebo placebo-controlled porphyria positive Pregnancy protocol psoriasis random randomisation randomised randomised controlled trial randomized clinical trial Randomly randomly divided receive recruitment Registered registry renal renal disease renal failure reported Research question researcher respiration rate responsible Rilpivirine Sample size sample size calculation sequence sequence information single-blind Siponimod Standard study drug Study protocol subject submitted technology temperature the ethics committee therapy title Tizanidine transaminase Treatment treatment group Treatment protocol treatment protocols Trial registration two group two groups university Version website were measured written consent
[DOI] 10.1186/s13063-020-04773-6 PMC 바로가기 [Article Type] Letter

An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-10-132022-10-29
Journal: Trials [Category] COVID-19, MERS, SARS,

[키워드] 1:1 7-point ordinal scale adaptive Alfred Hospital allergy Antiviral Antiviral treatment Arm biomarkers of inflammation blinded to treatment childbearing potential clinical clinical benefit clinical symptom clinical trial Community Confirmed Contraception COVID-19 COVID-19 infection Day defined determine dialysis dissemination dose effective Efficacy element eligible enrolled enrolment Favipiravir female fertile GRADE hospitalisation hospitalised immune activation ineligible investigator male medication negative pregnancy test nucleic acid number objective outcome parallel-group participant Participants Patient performed Pharmacy Placebo protocol randomisation randomised randomised controlled trial recruit recruited recruitment renal impairment Sample size SARS-CoV-2 Screening secondary severe hepatic dysfunction Standard of care status stratified Study protocol study visit Swab Symptom the WHO time Treatment Trial triple-blind Victoria virological cure website
[DOI] 10.1186/s13063-020-04766-5 PMC 바로가기 [Article Type] Letter

May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients?

Viewpoint

Published on 2020-10-102022-10-28
Journal: The Cochrane database of systematic reviews [Category] COVID-19,

[키워드] accompanied acute respiratory syndrome administration Affect aggregation appear approach Better Cardiopulmonary characterized chronic obstructive clinical settings clinical trial Compound Concentration contrast agent coronavirus COVID-19 COVID-19 patient disease dismutase double-blind Efficacy Endothelium enzyme expected form GC4419 inactivation Inc Inflammation Inflammatory Inflammatory response inhibit kill life-threatening low molecular weight lung epithelial cell magnetic resonance imaging mangafodipir manganese manuscript MnSOD MnSOD-mimetic MRI Neutralizing Nitrate nitric oxide organ organs Other Patient patients pharmaceutical pharmacological Platelet PROTECT pulmonary disease Randomized resulting risk SARS-CoV-2 SARS-CoV-2 patient SARS-CoV-2 patients shown submission Superoxide sustained thrombosis Treatment vasoconstriction widespread
[DOI] 10.3390/antiox9100971 PMC 바로가기 [Article Type] Viewpoint

Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‐19: An Open‐Label Randomized Controlled Pilot Study

Randomized Controlled Trial

Published on 2020-10-102022-10-04
Journal: Clinical and translational science [Category] SARS, 임상,

Traditional Herbal Medicine Candidates as Complementary Treatments for COVID-19: A Review of Their Mechanisms, Pros and Cons

Review Article

Published on 2020-10-102022-10-31
Journal: Evidence-based Complementary and Alternative Medicine : eCAM [Category] COVID-19,

Effects of Ginger on clinical manifestations and paraclinical features of patients with Severe Acute Respiratory Syndrome due to COVID-19: A structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-10-092022-10-29
Journal: Trials [Category] Coronavirus, MERS, SARS,

[키워드] 1:1 All study participants allergy antiarrhythmic drug anticipated Arm assigned Bandar Abbas blinded block randomization Breastfeeding C-reactive protein clinical clinical manifestation Clinical symptoms clinical trial Clinicians company Confirmed Control Corticosteroids COVID-19 criteria Critical Department Diagnosis disease Diseases disorder dissemination diuretics dose double-blind dry cough education Effect element Eligible participants exclusion criteria feature Features Fever GI symptom GI symptoms ginger history hypertension incidence Inclusion inhibitor investigator Iran liver lung involvement lymphocytopenia Ministry of Health number Nurses objective outcome parallel group participant Patient patients pharmaceutical placebo tablet placebo-controlled clinical trial Pneumonia polymerase chain Primary outcome protocol randomization Randomized Randomized controlled trial regimen Registered registration date registry renal Research respiratory Sample size SARS-CoV-2 secondary outcome selective Serious Adverse Event serotonin reuptake inhibitor Seven single center standard treatment status Study protocol Tablet therapeutic Thyroid time tiredness treatment arm two group Version web-based system website
[DOI] 10.1186/s13063-020-04765-6 PMC 바로가기 [Article Type] Letter